28 April, 2016 | ChargePoint Technology
Renowned for creating solutions in containment technology, ChargePoint has in recent years established itself as a leading valve manufacturer and there is growing demand for our products around the world.
The decision to relocate to a larger premises in Speke, Liverpool, was made to help us compete more effectively in the growing aseptic bio-pharma market and accommodate our flourishing business.
Manging Director Chris Eccles comments: “Our move is in line with both our growth and our ambition and drive to offer the highest quality products for sectors that need to use containment transfers.
“We have invested in state-of-the art technology to improve our unique and progressive devices and this commitment will be evident in the technology in development at present.
“We now have greater machine capability to increase our existing product range.”
ChargePoint is currently the number two manufacturer in the world for containment valves with 16 per cent of the market place and we are investing heavily in product development to become the major player for the technology, which is used for transferring raw materials safely and efficiently.
ChargePoint’s new hub is a 27,000/sq ft. production and office space and has been fitted out with more than £1m worth of state-of-the-art technology for the manufacturing of our cutting edge devices that are transforming the way medicines and vaccines are processed.
Within the building there is also a dedicated space for product demonstrations, training and customer visits and we will be installing clean rooms for future product assembly and testing.
Mr Eccles added: “The first quarter of 2016 showed phenomenal growth for the company and we have adapted to the demand around the world for our products. We want to show the world that we are a high precision manufacturing company surrounded by a cluster of world leading biopharma businesses in Speke and are now targeting an even larger market share.
“From our new premises, we are looking forward to meeting and exceeding the high expectations in the pharmaceutical and containment transfer markets and bolstering ChargePoint Technology’s reputation for innovation.”